Introduction. Multiple sclerosis (MS) is the most common neurological disease responsible
for early disability in the young working population. In the last two decades, based on …

Introduction: Despite recent advances in pharmacological management, multiple sclerosis
(MS), an autoimmune disease of the central nervous system, remains a leading cause of …

The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of
ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS). Data Sources: A …

Introduction: In the past decade, the role of B cells in the pathogenesis of multiple sclerosis
(MS) is coming to the forefront. Depletion of B cells by anti-CD20 monoclonal antibodies …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …

Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …